| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : Aqueous extractsType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Aqueous extracts of bulk spices 25 mg/mlDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Resut: Percent inhibition = 48.9+/-6.13
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : desmethoxyyangoninType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 217 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP1A2 inhibition = 1.70 micromolar lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 50.12 micromolar lC50 values (micromolar) of test compounds for CYP2C19 inhibition = 0.51 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BFC) inhibition = 20.02 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : dihydrokavainType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 215 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 130.95 micromolar lC50 values (micromolar) of test compounds for CYP2C19 inhibition = 10.05 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BFC) inhibition = 78.59 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : kavainType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 218 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP1A2 inhibition = 44.66 micromolar lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 128.30 micromolar lC50 values (micromolar) of test compounds for CYP2C19 inhibition = 4.86 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BFC) inhibition = 34.48 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : methysticinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 200 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP1A2 inhibition = 12.53 micromolar lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 16.39 micromolar lC50 values (micromolar) of test compounds for CYP2C19 inhibition = 0.93 micromolar lC50 values (micromolar) of test compounds for CYP2D6 inhibition = 153.20 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BzRes) inhibition = 10.20 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BFC) inhibition = 1.49 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : yangoninType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 175 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP1A2 inhibition = 19.87 micromolar lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 22.57 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : -Type of experiment : non specifiedType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Potent inhibitor of CYP3A4, CYP1A2, CYP2C9, CYP2D6, CYP2C19. Avoid with anticancer drugs and other sedatives.Note : Data from review, data incomplete.
